Literature DB >> 17584559

Validity of the Framingham point scores in the elderly: results from the Rotterdam study.

Michael T Koller1, Ewout W Steyerberg, Marcel Wolbers, Theo Stijnen, Heiner C Bucher, M G Myriam Hunink, Jacqueline C M Witteman.   

Abstract

BACKGROUND: The National Cholesterol Education Program recommends assessing 10-year risk of coronary heart disease (CHD) in individuals free of established CHD with the Framingham Point Scores (FPS). Individuals with a risk >20% are classified as high risk and are candidates for preventive intervention. We aimed to validate the FPS in a European population of elderly subjects.
METHODS: Subjects free of established CHD at baseline were selected from the Rotterdam study, a population-based cohort of subjects 55 years or older in The Netherlands. We studied calibration, discrimination (c-index), and the accuracy of high-risk classifications. Events consisted of fatal CHD and nonfatal myocardial infarction.
RESULTS: Among 6795 subjects, 463 died because of CHD and 336 had nonfatal myocardial infarction. Predicted 10-year risk of CHD was on average well calibrated for women (9.9% observed vs 10.1% predicted) but showed substantial overestimation in men (14.3% observed vs 19.8% predicted), particularly with increasing age. This resulted in substantial number of false-positive classifications (specificity 70%) in men. In women, discrimination of the FPS was better than that in men (c-index 0.73 vs 0.63, respectively). However, because of the low baseline risk of CHD and limited discriminatory power, only 33% of all CHD events occurred in women classified as high risk.
CONCLUSIONS: The FPS need recalibration for elderly men with better incorporation of the effect of age. In elderly women, FPS perform reasonably well. However, maintaining the rational of the high-risk threshold requires better performing models for a population with low incidence of CHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584559     DOI: 10.1016/j.ahj.2007.03.022

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

Review 1.  Current drug treatment of hyperlipidemia in older adults.

Authors:  Dave L Dixon; Krista L Donohoe; Kelechi C Ogbonna; Sarah M Barden
Journal:  Drugs Aging       Date:  2015-02       Impact factor: 3.923

2.  Cardiovascular risk and statin use in the United States.

Authors:  Michael Edward Johansen; Lee A Green; Ananda Sen; Sheetal Kircher; Caroline R Richardson
Journal:  Ann Fam Med       Date:  2014 May-Jun       Impact factor: 5.166

3.  Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative.

Authors:  Nancy R Cook; Nina P Paynter; Charles B Eaton; JoAnn E Manson; Lisa W Martin; Jennifer G Robinson; Jacques E Rossouw; Sylvia Wassertheil-Smoller; Paul M Ridker
Journal:  Circulation       Date:  2012-03-07       Impact factor: 29.690

4.  Development and validation of a coronary risk prediction model for older U.S. and European persons in the Cardiovascular Health Study and the Rotterdam Study.

Authors:  Michael T Koller; Maarten J G Leening; Marcel Wolbers; Ewout W Steyerberg; M G Myriam Hunink; Rotraut Schoop; Albert Hofman; Heiner C Bucher; Bruce M Psaty; Donald M Lloyd-Jones; Jacqueline C M Witteman
Journal:  Ann Intern Med       Date:  2012-09-18       Impact factor: 25.391

5.  Role of frailty assessment in patients undergoing cardiac interventions.

Authors:  Rebecca Rowe; Javaid Iqbal; Rachel Murali-Krishnan; Ayyaz Sultan; Rachel Orme; Norman Briffa; Martin Denvir; Julian Gunn
Journal:  Open Heart       Date:  2014-02-01

Review 6.  Frailty and cardiovascular disease: potential role of gait speed in surgical risk stratification in older adults.

Authors:  Michael A Chen
Journal:  J Geriatr Cardiol       Date:  2015-01       Impact factor: 3.327

7.  Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up study.

Authors:  Louise Gek Huang Goh; Timothy Alexander Welborn; Satvinder Singh Dhaliwal
Journal:  BMC Womens Health       Date:  2014-09-26       Impact factor: 2.809

8.  Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study.

Authors:  Amber A W A van der Heijden; Monica M Ortegon; Louis W Niessen; Giel Nijpels; Jacqueline M Dekker
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

9.  The Rotterdam Study: 2010 objectives and design update.

Authors:  Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Harry L A Janssen; Gabriel P Krestin; Ernst J Kuipers; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2009       Impact factor: 8.082

10.  Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to date.

Authors:  Thrasivoulos Tzellos; Athanassios Kyrgidis; Anastasia Trigoni; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2012-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.